Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women--the six-month effect of risedronate and teriparatide.
Τίτλος | Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women--the six-month effect of risedronate and teriparatide. |
Publication Type | Journal Article |
Year of Publication | 2012 |
Authors | Polyzos, S. A., Anastasilakis A. D., Bratengeier C., Woloszczuk W., Papatheodorou A., & Terpos E. |
Journal | Osteoporos Int |
Volume | 23 |
Issue | 3 |
Pagination | 1171-6 |
Date Published | 2012 Mar |
ISSN | 1433-2965 |
Λέξεις κλειδιά | Aged, Aged, 80 and over, Biomarkers, Bone Density, Bone Density Conservation Agents, Bone Morphogenetic Proteins, Bone Remodeling, Etidronic Acid, Female, Genetic Markers, Humans, Lumbar Vertebrae, Middle Aged, Osteoporosis, Postmenopausal, Postmenopause, Retrospective Studies, Risedronic Acid, Teriparatide |
Abstract | UNLABELLED: Sclerostin is expressed by osteocytes and inhibits bone formation by osteoblasts. In this study, serum sclerostin was positively correlated with either lumbar spinal bone mineral density or T-score. Furthermore, serum sclerostin was increased after 6 months treatment with risedronate, whereas remained unchanged after 6 months teriparatide treatment. |
DOI | 10.1007/s00198-010-1525-6 |
Alternate Journal | Osteoporos Int |
PubMed ID | 21305266 |